Top Industry Leaders in the Schizophrenia Market
Latest Schizophrenia Companies Updates:
Reviva Pharmaceuticals' brilaroxazine achieved statistically significant improvement in schizophrenia symptoms compared to placebo in a recent Phase 3 trial, potentially offering a new antipsychotic option.
Karuna Therapeutics' KarXT also demonstrated efficacy in its Phase 3 trial, but concerns about hypertension require further investigation.
Focus on novel mechanisms and targets: Companies are exploring drugs targeting the N-methyl-D-aspartate (NMDA) receptor, serotonin systems, and other pathways to address unmet needs in schizophrenia treatment.
Gene editing and personalized medicine approaches: Research is ongoing on utilizing gene editing to potentially treat the underlying causes of schizophrenia, offering long-term solutions.
Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, highlighting industry interest in novel schizophrenia treatments.
AbbVie enters a new co-development and license agreement with Gedeon Richter to research and develop novel dopamine receptor modulators for neuropsychiatric diseases, including schizophrenia.
List of Schizophrenia Key companies in the market:
- Johnson & Johnson
- Bristol-Myers Squibb and Company/Otsuka Pharmaceuticals
- AstraZeneca
- Eli Lilly
- Alkermes
- Sumitomo Dainippon Pharma
- Pfizer
- Vanda Pharmaceuticals
- Allergan/Geodon Ritcher